Suzhou Zelgen Biopharmaceuticals Co Ltd (688266)

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for hemostasis. It also develops gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, moderate to severe plaque psoriasis, idiopathic pulmonary fibrosis, and myelofibrosis; recombinant human thyroid-stimulating hormone for injection; and ZG006 for injection, indications for small cell lung cancer, neuroendocrine carcinoma, and other advanced tumors. In addition, it develops ZG005 for injection, which is in phase I/II clinical trial for cervical cancer, liver cancer, neuroendocrine carcinoma and other advanced tumors; and ZGGS18, ZGGS15, ZGGS34, ZG016, ZG2273, ZG2001film, and ZG0895 hydrochloric acid for injection indications for advance tumors. The company's products are used in multiple therapeutic areas, such as tumors and hematological diseases, bleeding and trauma, and immune inflammatory diseases. Suzhou Zelgen Biopharmaceuticals Co., Ltd. was founded in 2009 and is based in Kunshan, the People's Republic of China.